GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Loans Receivable

Orphazyme AS (CHIX:ORPHAC) Loans Receivable : kr0.00 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Loans Receivable?

Orphazyme AS's Loans Receivable for the quarter that ended in Jun. 2022 was kr0.00 Mil.


Orphazyme AS Loans Receivable Historical Data

The historical data trend for Orphazyme AS's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Loans Receivable Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Loans Receivable
Get a 7-Day Free Trial - - - - -

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Orphazyme AS Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Orphazyme AS Loans Receivable Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines